EUVIMEDEUVIMED entdecken
Systematische Übersicht

Assessment of US Food and Drug Administration–Approved Digital Medical Devices for Just-in-Time Interventions

Ngan Thi Thuy Phi, Theodora Oikonomidi, Philippe Ravaud, Viet-Thi Tran

JAMA Internal Medicine · 01.08.2023 · 183 (8) · 858

DOI: 10.1001/jamainternmed.2023.2864 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Internal Medicine, erschienen am 01.08.2023. Verfasst von Ngan Thi Thuy Phi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and Statistics (CRESS), F-75004 Paris, F…. Hauptthemen laut MEDLINE: Device Approval, Product Surveillance, Postmarketing. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Just-in-time interventions (JITIs) are a type of digital therapeutic intervention that combines remote monitoring tools and algorithms to personalize the delivery of specific interventions at the right time. The US Food and Drug Administration (FDA) regulatory approval documents are often the only available source of information on the effectiveness of therapeutic interventions based on these devices.

Objective

To systematically review the publicly available information from the FDA on all recently approved medical devices used in JITIs to (1) assess how they operate to deliver JITIs and (2) appraise the evidence supporting their performance and clinical effectiveness. Evidence Review Two reviewers systematically searched the Premarket Notifications (510(k)), Premarket Approvals, De Novo, and Humanitarian Device Exemption databases from January 2019 to December 2021 for all entries associated with devices that monitored patients’ data over time to personalize the delivery of interventions to treat, prevent, or mitigate health conditions or events. They assessed whether the product summaries (1) enabled an understanding of how the device operated to deliver a JITI (eg, the nature, type, and frequency of the monitoring, the nature of the decision algorithm, and the nature and intended receiver of the intervention); (2) informed about the performance and effectiveness of the JITI; and (3) included information on data security and ownership.

Findings

In total, 38 devices were included in this review. These were mainly intended for cardiac conditions (12 [31.6%]), diabetes (10 [26.3%]), and neurological diseases (4 [10.5%]). Monitoring devices ranged from wearable (18 of 28 [64.4%]; eg, smartwatches) to implanted sensors (6 of 28 [21.4%]; eg, inserted electrocardiographic sensors). Only 10 of 38 product summaries (26.3%) allowed a full understanding of how the device operated to deliver a JITI. Similarly, only 12 of 28 (42.9%), 12 of 36 (33.3%), and 5 of 38 (13.2%) reported the assessment of the performance of the monitoring device, assessment of the decision algorithm, and results of clinical studies assessing the effectiveness of the JITI, respectively. Finally, 14 of 36 product summaries (38.9%) included some information on data security, but none included information on data ownership. Conclusion and Relevance The results of this systematic review suggest that the information publicly available in the FDA databases on the performance and effectiveness of digital medical devices used in JITIs is heterogeneous.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Device ApprovalProduct Surveillance, PostmarketingHumansCompassionate Use TrialsDatabases, FactualUnited StatesUnited States Food and Drug Administration

Autor:innen und Institutionen

  • Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and Statistics (CRESS), F-75004 Paris, France.
  • Centre for Health Informatics, Division of Informatics, Imaging and Data Science, Manchester Academic Health Science Centre, University of Manchester, Manchester, England.
  • National Institute for Health and Care Research Applied Research Collaboration Greater Manchester, Manchester, England.
  • Centre d'Epidemiologie clinique, AP-HP, Hôpital Hôtel Dieu, F-75004 Paris, France.
  • Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.

Zitieren

APA

Phi, N. T. T., Oikonomidi, T., Ravaud, P., & Tran, V. T. (2023). Assessment of US Food and Drug Administration–Approved Digital Medical Devices for Just-in-Time Interventions. JAMA Internal Medicine, 183(8), 858. https://doi.org/10.1001/jamainternmed.2023.2864

Vancouver

Phi NTT, Oikonomidi T, Ravaud P, Tran VT. Assessment of US Food and Drug Administration–Approved Digital Medical Devices for Just-in-Time Interventions. JAMA Internal Medicine. 2023;183(8):858. doi:10.1001/jamainternmed.2023.2864

BibTeX
@article{Phi2023,
  author = {Phi, Ngan Thi Thuy and Oikonomidi, Theodora and Ravaud, Philippe and Tran, Viet-Thi},
  title = {Assessment of US Food and Drug Administration–Approved Digital Medical Devices for Just-in-Time Interventions},
  journal = {JAMA Internal Medicine},
  year = {2023},
  volume = {183},
  number = {8},
  pages = {858},
  doi = {10.1001/jamainternmed.2023.2864}
}
Kostenlos starten →